{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypertension-not-diabetic/prescribing-information/beta-blockers/","result":{"pageContext":{"chapter":{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers","depth":2,"htmlHeader":"<!-- begin field cbc89794-ae7a-4668-99b4-a71600db5993 --><h2>Beta-blockers</h2><!-- end field cbc89794-ae7a-4668-99b4-a71600db5993 -->","summary":"","htmlStringContent":"<!-- begin item e3b5e884-300b-4e9d-a8e1-a71600db59fa --><!-- end item e3b5e884-300b-4e9d-a8e1-a71600db59fa -->","topic":{"id":"c1c1e500-a3f1-5baa-8d5f-890b15f767cc","topicId":"8de59d12-a526-4ab9-8496-1fcb59d838ff","topicName":"Hypertension - not diabetic","slug":"hypertension-not-diabetic","lastRevised":"Last revised in September 2020","chapters":[{"id":"2f82c42a-b82b-549e-9b10-218d9f782bf8","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"a5985652-a8b7-51c0-b2d2-6836d4507f90","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"95f1a40b-c079-5c37-af45-5e0806a2bcae","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"4f16b189-bff9-5dfe-82a9-fdd4cd035ab0","slug":"changes","fullItemName":"Changes"},{"id":"a4dad1ea-40da-5ed2-85b0-8b5ea72bc196","slug":"update","fullItemName":"Update"}]},{"id":"b0107535-58ec-5e22-ac3b-22ae41ade390","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f76e08e3-badc-526a-835f-8f549cc3f784","slug":"goals","fullItemName":"Goals"},{"id":"928c1147-d56a-5b8a-94f7-87ddad3ef460","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aae28613-e6a5-5ba1-b4fa-e5032a9918ac","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7bf8c570-8757-5ae3-802f-5cba9e5ceb86","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3ace22a3-d042-5a6a-9d63-3527cf484a0a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c1a38cc6-4765-5c16-9f08-592cfc9851a3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"066993d8-fd33-59fb-877b-6e8418b515d1","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"15ade196-5491-5552-9df6-a17d4c9c69d7","slug":"definition","fullItemName":"Definition"},{"id":"4528059a-b33b-51d3-8c65-983b4c165a3a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"3e698434-11c9-553c-96a6-a249bf121cbb","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"0bec257d-f02e-5030-a430-8accc5245e7f","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"e56e7d7e-9afc-5c38-a77a-8f2b80461457","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"7dcedb3e-c4f4-55ff-9910-03ee5ed41bb4","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"a6466983-7adb-5a4f-8864-f3ecc06b447a","slug":"investigations","fullItemName":"Investigations"}]},{"id":"33227758-4699-5e51-be33-b22dca2eb654","fullItemName":"Management","slug":"management","subChapters":[{"id":"d6332f04-a86e-56ef-9e25-d77083a8371c","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"92190a49-9e8d-5fae-93b2-cf6243cfc01b","slug":"angiotensin-converting-enzyme-inhibitors","fullItemName":"Angiotensin-converting enzyme inhibitors"},{"id":"5ee249d0-bc66-59a5-8138-2449798ff2eb","slug":"angiotensin-ii-receptor-blockers","fullItemName":"Angiotensin-II receptor blockers"},{"id":"115bec24-ba4e-5f2a-80dc-dee6e948a288","slug":"thiazide-type-diuretics","fullItemName":"Thiazide-type diuretics"},{"id":"2ae4ccdd-d119-5a5a-9c89-d6493f2552f2","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"44681f3b-7958-5edd-a944-eb440f1df250","slug":"spironolactone","fullItemName":"Spironolactone"},{"id":"cb9a67f7-3588-5c68-b3d5-6c63d50ad0b8","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"5740c79c-d5a7-5547-ab38-db87df2b9121","slug":"alpha-blockers","fullItemName":"Alpha-blockers"},{"id":"f3424e7c-5446-59b0-b50e-0724587bb306","slug":"covid-19","fullItemName":"COVID-19"}]},{"id":"3b3191c9-bff5-563f-b5c0-09e8a0d22441","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"7d204db0-8ff2-556e-97b4-89516ac7819b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"0f686cda-dcaf-5f12-b5d6-871aefae47fe","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"dfcaec55-3c23-5a3f-9c08-f151a3120dc2","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"804073cd-b49f-5e4a-bf85-90faf125ad0e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"613e4289-93db-5311-aa87-b5a7a6e82dd1","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6e42a873-c39f-5405-bf4f-efdd81187ea2","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"2b87bc1c-2b4a-556b-b320-6b4f18bcf85d","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"0cfca07e-cadc-55c1-81ed-fcdb236f4835","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"ba37e950-43e8-5f51-a08f-449e9f76d0c6","slug":"choice-of-beta-blocker","fullItemName":"Choice of beta-blocker","depth":3,"htmlHeader":"<!-- begin field c29b8273-d34e-4155-886b-a71a00cacd46 --><h3>Which beta-blocker is recommended?</h3><!-- end field c29b8273-d34e-4155-886b-a71a00cacd46 -->","summary":"","htmlStringContent":"<!-- begin item 169bd50a-3297-42ef-9a69-a71a00cace65 --><!-- begin field 39a33da5-ae8b-4b69-a5aa-a71a00cacd46 --><ul><li>The choice of beta-blocker usually depends on the person's co-morbidities, local recommendations, and cost.</li><li>Where possible, prescribe a drug that is taken only once a day and prescribe non-proprietary drugs where these are appropriate and minimise cost.<ul><li>For people with hypertension and heart failure, bisoprolol, carvedilol, or nebivolol may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li><li>For people with hypertension and angina, atenolol, bisoprolol, or metoprolol may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>.</li></ul></li><li>For people who have hypertension and have had a previous myocardial infarction (without heart failure), metoprolol (standard release), propranolol (standard release), timolol, or atenolol may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">NICE, 2019</a>] </p><!-- end field 39a33da5-ae8b-4b69-a5aa-a71a00cacd46 --><!-- end item 169bd50a-3297-42ef-9a69-a71a00cace65 -->","subChapters":[]},{"id":"1a5824c0-1e66-5ef3-aa8d-aa1ea0adc604","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9d07523b-1b91-4f98-bf3e-a71a00cae541 --><h3>Contraindications and cautions</h3><!-- end field 9d07523b-1b91-4f98-bf3e-a71a00cae541 -->","summary":"","htmlStringContent":"<!-- begin item 4cc83ab3-44f6-4bf0-9f4b-a71a00cae6a9 --><!-- begin field b58f97db-3798-4c8b-b6e3-a71a00cae541 --><ul><li><strong>Do not prescribe beta-blockers to people with:</strong><ul><li>A history of obstructive airways disease (such as asthma and chronic obstructive pulmonary disease) or bronchospasm. However, if there is no alternative, a cardioselective beta-blocker (such as bisoprolol and atenolol) can be used under specialist supervision.<ul><li>Treatment should be initiated at the lowest possible dose and the person should be monitored for new symptoms (such as dyspnea or exercise intolerance). Concomitant bronchodilator therapy is recommended.</li></ul></li><li>Cardiogenic shock or phaeochromocytoma (without a concomitant alpha-blocker).</li><li>Second- or third-degree heart block (in the absence of a permanent pacemaker).</li><li>Sick sinus syndrome.</li><li>Sinus bradycardia (heart rate less than 60 beats per minute at the start of treatment).</li><li>Severe hypotension (systolic less than 100 mmHg).</li><li>Severe peripheral arterial disease (pain at rest and sometimes intermittent claudication) — the blood pressure-lowering properties of beta-blockers can exacerbate symptoms.</li><li>Uncontrolled heart failure.<ul><li>Seek specialist advice before starting a beta-blocker in people with a current or recent exacerbation of heart failure.</li></ul></li></ul></li><li><strong>Beta-blockers should be used with caution in people with:</strong><ul><li>Diabetes.</li><li>First-degree atrioventricular (AV) block.</li><li>Myasthaenia gravis.</li><li>Portal hypertension — due to risk of deteriorating liver function.</li><li>Psoriasis.</li><li>Note: Be aware that use of a beta-blocker can mask symptoms of hypoglycaemia and thyrotoxicosis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016p</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field b58f97db-3798-4c8b-b6e3-a71a00cae541 --><!-- end item 4cc83ab3-44f6-4bf0-9f4b-a71a00cae6a9 -->","subChapters":[]},{"id":"42f2e14a-7823-5651-aa93-92440a13ea5f","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1572a645-e314-4847-8018-a71a00cb0917 --><h3>Adverse effects</h3><!-- end field 1572a645-e314-4847-8018-a71a00cb0917 -->","summary":"","htmlStringContent":"<!-- begin item ac93cc0a-4f38-4376-ab49-a71a00cb0a65 --><!-- begin field 04c7737c-f017-43e7-af45-a71a00cb0917 --><p><strong>Adverse effects of beta-blockers include:</strong></p><ul><li>Bradycardia.</li><li>Bronchospasm.</li><li>Cold extremities, paraesthesiae, and numbness — these are more common in people with peripheral vascular disease.<ul><li>If troublesome, beta-blockers might need to be stopped.</li></ul></li><li>Conduction disorders.</li><li>Dizziness.</li><li>Dyspnoea.</li><li>Exacerbation of psoriasis.</li><li>Exacerbation of Raynaud's phenomenon.</li><li>Fatigue — an incidence of approximately 18 per 1,000 people treated with a beta-blocker has been reported.</li><li>Gastrointestinal disturbances.</li><li>Headache.</li><li>Heart failure.</li><li>Hyperglycaemia/hypoglycaemia— in people with or without diabetes.</li><li>Hypotension.</li><li>Impotence and loss of libido — occurs in approximately five people per 1,000 receiving treatment.</li><li>Paraesthesia.</li><li>Peripheral vasoconstriction.</li><li>Psychoses.</li><li>Purpura.</li><li>Sleep disturbance or nightmares — this occurs less frequently with water-soluble beta-blockers, such as atenolol, because these drugs are less likely to cross the blood-brain barrier.</li><li>Thrombocytopenia.</li><li>Vertigo.</li><li>Visual disturbances.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016p</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 04c7737c-f017-43e7-af45-a71a00cb0917 --><!-- end item ac93cc0a-4f38-4376-ab49-a71a00cb0a65 -->","subChapters":[]},{"id":"b9673067-396a-5de4-aca4-9c990a8dfb6f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field c4a7a610-7757-4b87-bb37-a71a00cb4a87 --><h3>Drug interactions</h3><!-- end field c4a7a610-7757-4b87-bb37-a71a00cb4a87 -->","summary":"","htmlStringContent":"<!-- begin item 514c7034-0e87-457e-a47d-a71a00cb4ba6 --><!-- begin field 5c7442f1-92f2-4f8d-8c6c-a71a00cb4a87 --><p><strong>Drug interactions with beta-blockers include:</strong></p><ul><li><strong>Alpha-blockers, alprostadil, ACE-inhibitors, angiotensin-II receptor blockers, anxiolytics, baclofen, co-beneldopa, co-careldopa, diazoxide, diuretics. hydralazine, hypnotics, levodopa, MAOIs, methyldopa, minoxidil, moxonidine, nitrates, phenothiazines, sodium nitroprusside, tizanidine </strong>— enhanced hypotensive effect.</li><li><strong>Antidepressants</strong><ul><li>Tricyclics, mirtazapine, and trazodone should be prescribed with caution in people taking beta-blockers, as there is an increased risk of postural hypotension.</li></ul></li><li><strong>Antidiabetics</strong> — beta-blockers may mask warning signs of hypoglycaemia, such as tremor.</li><li><strong>Calcium channel blockers</strong><ul><li>The combination of a beta-blocker and verapamil should not be prescribed because bradycardia, asystole, severe hypotension, and heart failure can occur.</li><li>Caution should be used if prescribing diltiazem with a beta-blocker — monitor pulse and blood pressure carefully, as bradycardia and atrioventricular block can occur. Asystole and sudden death have also been reported.</li><li>The combination of a beta-blocker and nifedipine can cause severe hypotension and heart failure.</li><li>The combination of a beta-blocker and other calcium channel blockers can lead to enhanced antihypertensive effect.</li></ul></li><li><strong>Class I </strong><strong>anti-arrhythmics</strong><strong> (such as quinidine, flecainide)</strong><ul><li>The combination of a beta-blocker and a class I anti-arrhythmic is not recommended because bradycardia and myocardial depression can occur.</li></ul></li><li><strong>Class III </strong><strong>anti-arrhythmics</strong><strong> (such as amiodarone)</strong><ul><li>The combination of a beta-blocker and amiodarone should be prescribed with caution as there is an increased risk of bradycardia, atrioventricular (AV) block, and myocardial depression — monitor pulse and blood pressure and check for signs of worsening heart failure.</li></ul></li><li><strong>Clonidine </strong>— increased risk of withdrawal hypertension. Withdraw beta-blockers several days before slowly withdrawing clonidine.</li><li><strong>Corticosteroids, oestrogens</strong> — hypotensive effect antagonised with concomitant use.</li><li><strong>Digoxin</strong><ul><li>Concomitant administration of a beta-blocker and digoxin can reduce heart rate and prolong AV conduction time, increasing the risk of AV block and bradycardia. Monitor the pulse carefully; consider monitoring with electrocardiography (ECG).</li><li>An increase in plasma digoxin levels has been noted with carvedilol — monitor for signs of digoxin toxicity (confusion, anorexia, nausea, disturbance of colour vision) when starting, adjusting, or stopping carvedilol.</li></ul></li><li><strong>Dobutamine</strong> — increased risk of severe hypertension and bradycardia when non-cardioselective beta-blockers (nadolol, oxprenolol, pindolol, propranolol, timolol) are given with dobutamine.</li><li><strong>Fingolimod, mefloquine</strong> — increased risk of bradycardia </li><li><strong>Moxisylyte </strong>— increased risk of severe postural hypotension.</li><li><strong>Non-steroidal anti-inflammatory drugs</strong> — hypotensive effect antagonised with concomitant use.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016p</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 5c7442f1-92f2-4f8d-8c6c-a71a00cb4a87 --><!-- end item 514c7034-0e87-457e-a47d-a71a00cb4ba6 -->","subChapters":[]},{"id":"210ef291-6dec-51e8-95b7-8eaab4d7197b","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 346b237c-f23d-49df-882c-a71a00cb0563 --><h3>Dose and titration</h3><!-- end field 346b237c-f23d-49df-882c-a71a00cb0563 -->","summary":"","htmlStringContent":"<!-- begin item 19265cc0-3a91-44da-a7ca-a71a00caf8dd --><!-- begin field 7e108933-de37-478d-bc3c-a71a00cb0563 --><ul><li><strong>Acebutolol</strong><ul><li>Initially, prescribe 400 mg daily in up to two divided doses.</li><li>If necessary, increase doses at an interval of two weeks.</li><li>The maximum dose is 1.2 g daily.</li></ul></li><li><strong>Atenolol</strong><ul><li>The usual dose is 25–50 mg daily (single dose). </li><li>If necessary, increase doses at an interval of two weeks.</li><li>The maximum dose is 100 mg daily (single dose).</li></ul></li><li><strong>Bisoprolol</strong><ul><li>Initially prescribe 5 mg daily.</li><li>The usual dose is 10 mg daily (single dose taken in the morning). </li><li>The maximum dose is 20 mg daily (single dose taken in the morning).</li></ul></li><li><strong>Carvedilol</strong><ul><li>Initially, prescribe 12.5 mg once daily for 2 days, then increase to 25 mg once a day (12.5 mg daily may provide adequate control in elderly people).</li><li>The maximum dose is 50 mg daily, in single or divided doses.</li><li>Increase doses at an interval of at least two weeks.</li></ul></li><li><strong>Celiprolol</strong><ul><li>Initially prescribe 200 mg daily (single dose taken in the morning). </li><li>If necessary, increase the dose at intervals of 2–4 weeks to a maximum of 400 mg daily (single dose taken in the morning).</li></ul></li><li><strong>Labetolol</strong><ul><li>Initially, prescribe 100 mg twice daily (50 mg twice daily to be used in elderly people).</li><li>If necessary, increase doses at an interval of two weeks. The usual dose is 200 mg twice daily.</li><li>Doses of up to 800 mg can be given as two divided doses to be taken with food.</li><li>The maximum dose is 2.4 g daily, in 3–4 divided doses.</li></ul></li><li><strong>Metoprolol</strong><ul><li>For immediate-release preparations:<ul><li>Initially, prescribe 100 mg daily.</li><li>If necessary, increase to 200 mg daily in 1 or 2 doses.</li><li>The maximum dose is 400 mg daily.</li></ul></li><li>For modified-release preparations, prescribe 200 mg once daily.</li></ul></li><li><strong>Nadolol</strong><ul><li>Initially, prescribe 80 mg once daily.</li><li>If necessary, increase in steps of up to 80 mg each week.</li><li>The maximum dose is 240 mg daily.</li></ul></li><li><strong>Nebivolol</strong><ul><li>The usual dose is 5 mg once daily.</li><li>In elderly people and people with renal impairment, initially prescribe 2.5 mg daily and increase to 5 mg daily if necessary. It may take up to four weeks for the optimum effect to be realised.</li></ul></li><li><strong>Oxprenolol</strong><ul><li>For immediate-release preparations:<ul><li>Initially, prescribe 80–160 mg daily in 2–3 divided doses.</li><li>If necessary, increase to a maximum of 320 mg daily.</li></ul></li><li>For modified-release preparations:<ul><li>Initially, prescribe 160 mg once daily.</li><li>If necessary, increase to a maximum of 320 mg daily.</li></ul></li></ul></li><li><strong>Pindolol</strong><ul><li>Initially, prescribe 10–15 mg daily in 2–3 divided doses.</li><li>If necessary, increase doses at weekly intervals. The usual dose is 15–30 mg daily.</li><li>The maximum dose is 45 mg daily.</li></ul></li><li><strong>Propranolol</strong><ul><li>Initially, prescribe 80 mg twice daily.</li><li>If necessary, increase doses at weekly intervals. The usual dose is 160–320 mg daily.</li></ul></li><li><strong>Timolol</strong><ul><li>Initially, prescribe 10 mg daily in up to two divided doses.</li><li>If necessary, increase doses gradually. The usual dose is 10–30 mg daily.</li><li>Doses of over 30 mg daily should be given in divided doses. The maximum daily dose is 60 mg.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2014c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015a</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2015b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI Medicines Compendium, 2015c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016p</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2016q</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017g</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017h</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">ABPI, 2017l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypertension-not-diabetic/references/\">BNF 73, 2017</a>]</p><!-- end field 7e108933-de37-478d-bc3c-a71a00cb0563 --><!-- end item 19265cc0-3a91-44da-a7ca-a71a00caf8dd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}